DURHAM – Durham-based Precision Biosciences’ genome editing technology has drawn interest – and investment – from another global pharmaceutical giant. This time it’s Novartis. The two companies have ...
FARMINGDALE, N.Y. - December 5, 2018 - Precision Label Corporation, a New York-based converter serving major cosmetic brands, is expanding its digital production capabilities with the addition of ...
Precision BioSciences Inc (NASDAQ: DTIL) and Tiziana Life Sciences plc (NASDAQ: TLSA) have announced an exclusive license agreement for Tiziana's foralumab. The companies plan to explore the fully ...
Under the agreement iECURE plans to advance Precision's PBGENE-PCSK9 candidate into Phase 1 studies and gain access to Precision's PCSK9-directed ARCUS nuclease to develop additional gene-editing ...
As fellow gene editing firm Crispr Therapeutics AG hosted an innovation day in which it confirmed plans for regulatory filings by year-end for an ex vivo gene editing therapy in sickle cell disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results